Kim J, Kesselheim AS, Rome BN - Journal of Managed Care & Specialty Pharmacy
- Commentary & Opinion
- Price, Value, and Access
Summary:
A loophole in Medicare drug price negotiation may enable manufacturers of certain intravenously infused biologic drugs to delay negotiation eligibility by launching subcutaneous versions of their products that contain hyaluronidase. CMS should prevent these reformulated versions from delaying price negotiation by bundling reformulated products with their originals to ensure the price negotiation is meeting its intended policy goals.
VIEW SOURCE
Recent Work from PORTAL
Pharmaceutical Industry Pay-Per-Click Advertising Strategies to Influence Public Opinions on Drug Pricing
Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics
- Research Publications
- Price, Value, and Access
Coverage and Costs for Medications After Medicare Price Negotiation
Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine
- Research Publications
- Price, Value, and Access
Methodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty
Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open
- Research Publications
- Price, Value, and Access
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.